Ionis Pharmaceuticals, Inc. Comprehensive Income
Ionis Pharmaceuticals, Inc. (IONS) reported Comprehensive Income of -$117.52 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-07-29
- Ionis Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$117.52M, a 194.38% decline year-over-year.
- Ionis Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$98.27M.
- Ionis Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$228.70M.
- Ionis Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$126.60M.
- Ionis Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$375.86M.
- Ionis Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$452.06M.
- Ionis Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$341.45M.
- Ionis Pharmaceuticals, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$294.53M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$117.52M 10-Q · filed 2026-07-29 | -$215.79M 10-Q · filed 2026-07-29 | -$444.49M derived: sum of 3 quarters · filed 2026-07-29 | -$571.08M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2026-03-31 | -$98.27M 10-Q · filed 2026-04-29 | -$326.97M derived: sum of 2 quarters · filed 2026-04-29 | -$453.56M derived: sum of 3 quarters · filed 2026-04-29 | -$329.05M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2025-12-31 | -$228.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$355.29M derived: sum of 2 quarters · filed 2026-02-26 | -$230.78M derived: sum of 3 quarters · filed 2026-07-29 | -$375.86M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | -$126.60M 10-Q · filed 2025-10-29 | -$2.08M derived: sum of 2 quarters · filed 2026-07-29 | -$147.16M 10-Q · filed 2025-10-29 | -$258.15M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2025-06-30 | $124.51M 10-Q · filed 2026-07-29 | -$20.56M 10-Q · filed 2026-07-29 | -$131.55M derived: sum of 3 quarters · filed 2026-07-29 | -$261.37M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2025-03-31 | -$145.08M 10-Q · filed 2026-04-29 | -$256.06M derived: sum of 2 quarters · filed 2026-04-29 | -$385.88M derived: sum of 3 quarters · filed 2026-04-29 | -$452.02M derived: sum of 4 quarters · filed 2026-04-29 | ||||
| 2024-12-31 | -$110.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$240.80M derived: sum of 2 quarters · filed 2026-02-26 | -$306.94M derived: sum of 3 quarters · filed 2026-02-26 | -$452.06M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | -$129.81M 10-Q · filed 2025-10-29 | -$195.95M derived: sum of 2 quarters · filed 2025-10-29 | -$341.08M 10-Q · filed 2025-10-29 | -$336.95M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-06-30 | -$66.14M 10-Q · filed 2025-07-30 | -$211.26M 10-Q · filed 2025-07-30 | -$207.13M derived: sum of 3 quarters · filed 2026-02-26 | -$349.67M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-03-31 | -$145.12M 10-Q · filed 2025-04-30 | -$140.99M derived: sum of 2 quarters · filed 2026-02-26 | -$283.53M derived: sum of 3 quarters · filed 2026-02-26 | -$370.75M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2023-12-31 | $4.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$138.41M derived: sum of 2 quarters · filed 2026-02-26 | -$225.63M derived: sum of 3 quarters · filed 2026-02-26 | -$341.45M 10-K · filed 2026-02-26 | ||||
| 2023-09-30 | -$142.53M 10-Q · filed 2024-11-06 | -$229.75M derived: sum of 2 quarters · filed 2024-11-06 | -$345.58M 10-Q · filed 2024-11-06 | -$392.35M derived: sum of 4 quarters · filed 2025-02-19 | ||||
| 2023-06-30 | -$87.22M 10-Q · filed 2024-08-01 | -$203.05M 10-Q · filed 2024-08-01 | -$249.82M derived: sum of 3 quarters · filed 2025-02-19 | -$305.94M derived: sum of 4 quarters · filed 2025-02-19 | ||||
| 2023-03-31 | -$115.83M 10-Q · filed 2024-05-07 | -$162.60M derived: sum of 2 quarters · filed 2025-02-19 | -$218.72M derived: sum of 3 quarters · filed 2025-02-19 | -$329.29M derived: sum of 4 quarters · filed 2025-02-19 | ||||
| 2022-12-31 | -$46.77M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | -$102.89M derived: sum of 2 quarters · filed 2025-02-19 | -$213.46M derived: sum of 3 quarters · filed 2025-02-19 | -$294.53M 10-K · filed 2025-02-19 | ||||
| 2022-09-30 | -$56.13M 10-Q · filed 2023-11-02 | -$166.69M derived: sum of 2 quarters · filed 2023-11-02 | -$247.76M 10-Q · filed 2023-11-02 | -$28.38M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2022-06-30 | -$110.56M 10-Q · filed 2023-08-09 | -$191.64M 10-Q · filed 2023-08-09 | $27.74M derived: sum of 3 quarters · filed 2024-02-21 | -$56.36M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2022-03-31 | -$81.08M 10-Q · filed 2023-05-03 | $138.31M derived: sum of 2 quarters · filed 2024-02-21 | $54.20M derived: sum of 3 quarters · filed 2024-02-21 | -$28.27M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2021-12-31 | $219.38M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $135.28M derived: sum of 2 quarters · filed 2024-02-21 | $52.81M derived: sum of 3 quarters · filed 2024-02-21 | -$40.19M 10-K · filed 2024-02-21 | ||||
| 2021-09-30 | -$84.11M 10-Q · filed 2022-11-09 | -$166.57M derived: sum of 2 quarters · filed 2022-11-09 | -$259.58M 10-Q · filed 2022-11-09 | -$615.61M derived: sum of 4 quarters · filed 2023-02-22 | ||||
| 2021-06-30 | -$82.47M 10-Q · filed 2022-08-09 | -$175.47M 10-Q · filed 2022-08-09 | -$531.50M derived: sum of 3 quarters · filed 2023-02-22 | -$559.10M derived: sum of 4 quarters · filed 2023-02-22 | ||||
| 2021-03-31 | -$93.00M 10-Q · filed 2022-05-04 | -$449.03M derived: sum of 2 quarters · filed 2023-02-22 | -$476.63M derived: sum of 3 quarters · filed 2023-02-22 | -$491.47M derived: sum of 4 quarters · filed 2023-02-22 | ||||
| 2020-12-31 | -$356.03M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | -$383.63M derived: sum of 2 quarters · filed 2023-02-22 | -$398.47M derived: sum of 3 quarters · filed 2023-02-22 | -$440.04M 10-K · filed 2023-02-22 | -$447.07M 10-K · filed 2021-02-24 | |||
| 2020-09-30 | -$27.60M 10-Q · filed 2021-11-03 | -$34.08M 10-Q · filed 2020-11-04 | -$42.44M derived: sum of 2 quarters · filed 2021-11-03 | -$84.01M 10-Q · filed 2021-11-03 | -$105.30M 10-Q · filed 2020-11-04 | $84.49M derived: sum of 4 quarters · filed 2022-02-25 | ||
| 2020-06-30 | -$14.84M 10-Q · filed 2021-08-04 | -$21.05M 10-Q · filed 2020-08-05 | -$56.41M 10-Q · filed 2021-08-04 | -$71.22M 10-Q · filed 2020-08-05 | $112.09M derived: sum of 3 quarters · filed 2022-02-25 | $137.13M derived: sum of 4 quarters · filed 2022-02-25 | ||
| 2020-03-31 | -$41.57M 10-Q · filed 2021-05-05 | -$50.17M 10-Q · filed 2020-05-06 | $126.93M derived: sum of 2 quarters · filed 2022-02-25 | $151.97M derived: sum of 3 quarters · filed 2022-02-25 | $154.45M derived: sum of 4 quarters · filed 2022-02-25 | |||
| 2019-12-31 | $168.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $193.54M derived: sum of 2 quarters · filed 2022-02-25 | $196.02M derived: sum of 3 quarters · filed 2022-02-25 | $284.87M 10-K · filed 2022-02-25 | $300.87M 10-K · filed 2020-03-02 | |||
| 2019-09-30 | $25.04M 10-Q · filed 2020-11-04 | $25.04M 10-Q · filed 2019-11-06 | $27.52M derived: sum of 2 quarters · filed 2020-11-04 | $116.37M 10-Q · filed 2020-11-04 | $440.39M derived: sum of 4 quarters · filed 2021-02-24 | |||
| 2019-06-30 | $2.48M 10-Q · filed 2020-08-05 | $91.33M 10-Q · filed 2020-08-05 | $415.36M derived: sum of 3 quarters · filed 2021-02-24 | $409.04M derived: sum of 4 quarters · filed 2021-02-24 | ||||
| 2019-03-31 | $88.85M 10-Q · filed 2020-05-06 | $88.85M 10-Q · filed 2019-05-09 | $412.88M derived: sum of 2 quarters · filed 2021-02-24 | $406.56M derived: sum of 3 quarters · filed 2021-02-24 | $365.25M derived: sum of 4 quarters · filed 2021-02-24 | |||
| 2018-12-31 | $324.02M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $317.70M derived: sum of 2 quarters · filed 2021-02-24 | $276.40M derived: sum of 3 quarters · filed 2021-02-24 | $273.51M 10-K · filed 2021-02-24 | ||||
| 2018-09-30 | -$6.32M 10-Q · filed 2019-11-06 | -$4.46M 10-Q · filed 2018-11-06 | -$47.63M derived: sum of 2 quarters · filed 2019-11-06 | -$50.52M 10-Q · filed 2019-11-06 | -$47.06M 10-Q · filed 2018-11-06 | -$53.97M derived: sum of 4 quarters · filed 2020-03-02 | ||
| 2018-06-30 | -$41.31M 10-Q · filed 2019-08-08 | -$39.74M 10-Q · filed 2018-08-07 | -$44.19M 10-Q · filed 2019-08-08 | -$42.60M 10-Q · filed 2018-08-07 | -$47.65M derived: sum of 3 quarters · filed 2020-03-02 | -$51.02M derived: sum of 4 quarters · filed 2020-03-02 | ||
| 2018-03-31 | -$2.89M 10-Q · filed 2019-05-09 | -$2.86M 10-Q · filed 2018-05-07 | -$6.34M derived: sum of 2 quarters · filed 2020-03-02 | -$9.71M derived: sum of 3 quarters · filed 2020-03-02 | -$12.71M derived: sum of 4 quarters · filed 2020-03-02 | |||
| 2017-12-31 | -$3.46M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | -$6.82M derived: sum of 2 quarters · filed 2020-03-02 | -$9.82M derived: sum of 3 quarters · filed 2020-03-02 | -$960.00K 10-K · filed 2020-03-02 | -$7.28M 10-K · filed 2018-02-28 | |||
| 2017-09-30 | -$3.37M 10-Q · filed 2018-11-06 | -$715.00K 10-Q · filed 2017-11-07 | -$6.37M derived: sum of 2 quarters · filed 2018-11-06 | $2.50M 10-Q · filed 2018-11-06 | -$8.56M 10-Q · filed 2017-11-07 | $50.65M derived: sum of 4 quarters · filed 2019-03-01 | ||
| 2017-06-30 | -$3.00M 10-Q · filed 2018-08-07 | -$11.12M 10-Q · filed 2017-08-09 | $5.86M 10-Q · filed 2018-08-07 | -$7.75M 10-Q · filed 2017-08-09 | $54.01M derived: sum of 3 quarters · filed 2019-03-01 | $61.72M derived: sum of 4 quarters · filed 2019-03-01 | ||
| 2017-03-31 | $8.85M 10-Q · filed 2018-05-07 | $3.35M 10-Q · filed 2017-05-09 | $57.01M derived: sum of 2 quarters · filed 2019-03-01 | $64.72M derived: sum of 3 quarters · filed 2019-03-01 | -$2.88M derived: sum of 4 quarters · filed 2019-03-01 | |||
| 2016-12-31 | $48.16M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $55.87M derived: sum of 2 quarters · filed 2019-03-01 | -$11.73M derived: sum of 3 quarters · filed 2019-03-01 | -$77.19M 10-K · filed 2019-03-01 | -$103.35M 10-K · filed 2017-03-01 | |||
| 2016-09-30 | $7.71M 10-Q · filed 2017-11-07 | -$59.89M derived: sum of 2 quarters · filed 2017-11-07 | -$125.35M 10-Q · filed 2017-11-07 | -$192.40M derived: sum of 4 quarters · filed 2018-02-28 | ||||
| 2016-06-30 | -$67.59M 10-Q · filed 2017-08-09 | -$133.06M 10-Q · filed 2017-08-09 | -$200.10M derived: sum of 3 quarters · filed 2018-02-28 | -$272.25M derived: sum of 4 quarters · filed 2018-02-28 | ||||
| 2016-03-31 | -$65.47M 10-Q · filed 2017-05-09 | -$132.51M derived: sum of 2 quarters · filed 2018-02-28 | -$204.65M derived: sum of 3 quarters · filed 2018-02-28 | -$197.71M derived: sum of 4 quarters · filed 2018-02-28 | ||||
| 2015-12-31 | -$67.04M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | -$139.19M derived: sum of 2 quarters · filed 2018-02-28 | -$132.24M derived: sum of 3 quarters · filed 2018-02-28 | -$141.59M 10-K · filed 2018-02-28 | ||||
| 2015-09-30 | -$72.14M 10-Q · filed 2016-11-09 | -$65.20M derived: sum of 2 quarters · filed 2016-11-09 | -$74.55M 10-Q · filed 2016-11-09 | -$20.64M derived: sum of 4 quarters · filed 2017-03-01 | ||||
| 2015-06-30 | $6.95M 10-Q · filed 2016-08-09 | -$2.40M 10-Q · filed 2016-08-09 | $51.50M derived: sum of 3 quarters · filed 2017-03-01 | $17.00M derived: sum of 4 quarters · filed 2017-03-01 | ||||
| 2015-03-31 | -$9.35M 10-Q · filed 2016-05-05 | $44.56M derived: sum of 2 quarters · filed 2017-03-01 | $10.05M derived: sum of 3 quarters · filed 2017-03-01 | -$6.31M derived: sum of 4 quarters · filed 2017-03-01 | ||||
| 2014-12-31 | $53.91M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $19.41M derived: sum of 2 quarters · filed 2017-03-01 | $3.04M derived: sum of 3 quarters · filed 2017-03-01 | -$20.32M 10-K · filed 2017-03-01 | ||||
| 2014-09-30 | -$34.50M 10-Q · filed 2015-11-09 | -$50.86M derived: sum of 2 quarters · filed 2015-11-09 | -$74.22M 10-Q · filed 2015-11-09 | -$106.44M derived: sum of 4 quarters · filed 2016-02-26 | ||||
| 2014-06-30 | -$16.36M 10-Q · filed 2015-08-05 | -$39.72M 10-Q · filed 2015-08-05 | -$71.94M derived: sum of 3 quarters · filed 2016-02-26 | -$94.47M derived: sum of 4 quarters · filed 2016-02-26 | ||||
| 2014-03-31 | -$23.36M 10-Q · filed 2015-05-05 | -$55.58M derived: sum of 2 quarters · filed 2016-02-26 | -$78.11M derived: sum of 3 quarters · filed 2016-02-26 | -$79.04M derived: sum of 4 quarters · filed 2016-02-26 | ||||
| 2013-12-31 | -$32.22M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | -$54.75M derived: sum of 2 quarters · filed 2016-02-26 | -$55.68M derived: sum of 3 quarters · filed 2016-02-26 | -$52.04M 10-K · filed 2016-02-26 | ||||
| 2013-09-30 | -$22.54M 10-Q · filed 2014-11-07 | -$23.46M derived: sum of 2 quarters · filed 2014-11-07 | -$19.83M 10-Q · filed 2014-11-07 | -$10.83M derived: sum of 4 quarters · filed 2015-03-02 | ||||
| 2013-06-30 | -$924.00K 10-Q · filed 2014-08-04 | $2.71M 10-Q · filed 2014-08-04 | $11.71M derived: sum of 3 quarters · filed 2015-03-02 | -$26.06M derived: sum of 4 quarters · filed 2015-03-02 | ||||
| 2013-03-31 | $3.63M 10-Q · filed 2014-05-06 | $12.63M derived: sum of 2 quarters · filed 2015-03-02 | -$25.13M derived: sum of 3 quarters · filed 2015-03-02 | -$25.13M derived: sum of 4 quarters · filed 2015-03-02 | ||||
| 2012-12-31 | $9.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | -$28.76M derived: sum of 2 quarters · filed 2015-03-02 | -$28.76M derived: sum of 3 quarters · filed 2015-03-02 | -$52.23M 10-K · filed 2015-03-02 | ||||
| 2012-09-30 | -$37.76M 10-Q · filed 2013-11-05 | -$37.76M derived: sum of 2 quarters · filed 2013-11-05 | -$61.23M 10-Q · filed 2013-11-05 | -$80.88M derived: sum of 4 quarters · filed 2014-03-03 | ||||
| 2012-06-30 | $3.00K 10-Q · filed 2013-08-06 | -$23.46M 10-Q · filed 2013-08-06 | -$43.12M derived: sum of 3 quarters · filed 2014-03-03 | -$71.55M derived: sum of 4 quarters · filed 2014-03-03 | ||||
| 2012-03-31 | -$23.47M 10-Q · filed 2013-05-07 | -$43.12M derived: sum of 2 quarters · filed 2014-03-03 | -$71.55M derived: sum of 3 quarters · filed 2014-03-03 | |||||
| 2011-12-31 | -$19.65M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | -$48.09M derived: sum of 2 quarters · filed 2014-03-03 | -$86.52M 10-K · filed 2014-03-03 | |||||
| 2011-09-30 | -$28.43M 10-Q · filed 2012-11-06 | -$66.87M 10-Q · filed 2012-11-06 | ||||||
| 2010-12-31 | -$62.45M 10-K · filed 2013-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |